Trial Profile
A Double-Blind, Randomized, Three-Arm, Parallel-Group Study to Assess the Efficacy and Safety of Two Doses of Pridopidine Versus Placebo for the Treatment of Levodopa-Induced Dyskinesia in Patients With Parkinson's Disease (gLIDe)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Jul 2022
Price :
$35
*
At a glance
- Drugs Pridopidine (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Acronyms gLIDe
- Sponsors Prilenia Therapeutics
- 05 Nov 2020 Status changed from active, no longer recruiting to discontinued.
- 11 Aug 2020 Protocol amended to change time frame from 14 weeks to 16 weeks.
- 11 Aug 2020 Planned End Date changed from 1 Apr 2020 to 1 Apr 2021.